Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +16

Extrapulmonary Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor) A Clinicopathologic and Immunohistochemical Study of 84 Cases

Cheryl M. Coffin, Jan Watterson, John R. Priest et al. · The American Journal of Surgical Pathology · 1995 · 1.6K citations

Medicine, Oncology, Pathology +13

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor

James E. Butrynski, David R. D’Adamo, Jason L. Hornick et al. · New England Journal of Medicine · 2010 · 867 citations

Veterinary Medicine, Cancer Biology, Oncology +17